BerGen Bio, Nexstim and AMRA receive Nordic Stars 2015 Awards


BerGen Bio, AMRA and Nexstim have been announced as the recipients of the Nordic Stars 2015 Awards. The awards were presented at the conclusion of the Nordic Life Science Days in Stockholm, which again set a new record for attendance, with over 1000 delegates from 31 countries, establishing itself as the premier Nordic life sciences event.

Nordic Stars Awards were introduced in 2013 in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.

“This year’s winner of the Nordic Stars Awards are clearly future-­‐oriented and committed to working in new ways to bring medical innovations to patients. They are both role models for others and an example of the innovation capacity in the life sciences in the Nordic countries “, says Jonas Ekstrand, Director General SwedenBIO.

This year’s winners are:

BerGen Bio
Norwegian BerGenBio’s commitment to develop companion diagnostics and first-­‐in-­‐ class drugs targeting the cellular processes that make cancer cells immune-­‐evasive, drug resistant and metastatic is a great example of what the future might hold. With focus on ground-­‐breaking therapies and precision medicine BerGenBio is a leading example and   a Nordic Star.

Norwegian NexStim’s development and commercialization of a non-­‐invasive technology to monitor and modulate brain function provides a good example of how an innovative combination of new and established treatment modalities could add significant value to patients. NextStims strategic management shows how to step by step bring an innovation to the market.

Swedish AMRA’s exciting technology that transforms MRI images into body composition measurements provides a solid basis for precision medicine approaches in the area of metabolic diseases. With innovative collaborations, AMRA shows how the combination of technology and cutting edge management brings new knowledge to the world.


Ekstrand also reflected on a highly successful two days: “NLSDays has continued to grow and established a strong reputation. We are particularly pleased to see the high level of international interest, which is a recognition of the thriving entrepreneurial life sciences environment here and we look forward to continuing to develop and expand NLSDays over the coming years. ”

The theme of the conference “The New Value Chain and the Future” was also well received, as was the focus on three trends -­‐ Digitalization, Precision and Preventive Medicine and Breakthrough Therapies. These are described in a brief report co-­‐written by SwedenBIO and Arthur D. Little that also outlines key factors for success for companies in these areas in the future.


Nordic Life Science Days 2016 will be held September 13-­‐15 in Stockholm.

Nordic Life Science Days 2015 in brief:

  • Registered Delegates: 1026
  • Registered Companies: 680
  • Countries Represented: 31 Partnering Meeting Requests: 9514 Partnering Meetings Scheduled: 1957 Licensing Opportunities: 541

NLSDays was founded in 2012 and has grown rapidly to become the largest Nordic partnering conference for the global life science industry. Among the investors and big pharma attending NLSDays 2015 were AbbVie, Alexion, Almi Invest, Astellas, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-­‐Myers Squibb, Cadila Pharma, Johnson & Johnson, HealthCap, Industrifonden, Karolinska Development, Merck-­‐MSD, Novartis, Pfizer, Pierre Fabre, P.U.LS. AB, Recipharm, Roche, Seventure Partners  and SR-­‐One.

In addition to partnering, NLSDays also offers an exhibition and a seminar program. Speakers include senior representatives from the global life science companies, investors, and academic leaders who will all share their expertise and views for the future.